Cytokinetics is the focus of takeover speculation, Ben Harrington’s Betaville blog said, contacts tell The Fly.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CYTK:
- Morgan Stanley Predicts at Least 70% Upside for These 2 High-Conviction Stocks — They Have Upcoming Catalysts and Strong Growth Prospects
- Morgan Stanley positive on Cytokinetics ahead of earnings
- Cytokinetics to Announce Third Quarter Results on November 2, 2023
- Cytokinetics price target raised to $58 from $49 at H.C. Wainwright
- Cytokinetics provide update on cardiac myosin inhibitor programs at Analyst Day